Yıl: 2019 Cilt: 56 Sayı: 1 Sayfa Aralığı: 23 - 26 Metin Dili: İngilizce DOI: 10.5152/npa.2017.19269 İndeks Tarihi: 02-09-2020

Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course

Öz:
Amaç: Primer progresif multipl skleroz (PPMS) ve progresif relapsingmultipl skleroz (PRMS) başlangıçtan beri olan progresyon ile karakterizeMS tipleridir. Nadir görülmelerinden dolayı, literatürde diğer MSformlarına göre daha az bilgi bulunmaktadır. Bu çalışmanın amacıprogresif başlangıçlı MS (PBMS) hastalarında klinik ve laboratuvarözelliklerini ortaya koymaktır.Yöntem: PBMS hastaları 2010–2014 yılları arasında değerlendirilipdemografik, klinik özellikleri ve beyin omurilik sıvısı (BOS) bulgularıbelirlendi.Bulgular: Otuz iki PBMS hastası ile ilgili veriler değerlendirildi. Hastalıkseyri 24 hastada relaps olmadan (PPMS), sekiz hastada ise relapslıprogresifti (PRMS). Kadın/erkek oranı tüm grupta 1’di. Ortalama başlangıçyaşı tüm grup için 40 (23–55) yaştı. Gruplar arasında hastalık başlangıçyaşı ortancası anlamlı farklı bulunmadı (p=0,053). En sık prezantasyonbelirtisi motor bozukluklardı. Relapslar tüm hastalarda hastalığın ilk 10yılında görüldü. BOS analizinde oligoklonal bant pozitifliği ve artmış IgGindeksi açısından gruplar arasında fark saptanmadı (p=0,938, p=0,058).Hastalık süresi her iki grupta da benzer olduğu halde, PPMS grubundadeğerlendirme sırasında ortanca EDSS skoru daha yüksek bulundu(p=0,020).Sonuç: Çalışmamız Türk PBMS hastalarının klinik seyir ve laboratuvarbulgularına odaklanmış ilk çalışmadır. İki grubun klinik ve laboratuvarbulgularının karşılaştırılması benzer sonuçlar göstermiştir. Gruplararasında hastalık başlangıç yaşı ve artmış IgG indeksi açısından farklılıkolup olmadığını netleştirmek için gelecekte daha geniş örneklemliçalışmalar yapılması gerekmektedir.
Anahtar Kelime:

Progresif Başlangıçlı Multipl Skleroz: Öyküsünde Relaps Olan ve Olmayan Hastaların Demografik, Klinik ve Laboratuvar Özellikleri

Öz:
Introduction: Primary progressive multiple sclerosis (PPMS) and progressive relapsing multiple sclerosis (PRMS) are the types of MS that are mainly characterized by progression from the onset. Because of their rare prevalence the knowledge is less than other forms in the literature. Hence, the aim of this study is to exhibit the clinical and laboratory characteristics of patients with progressive onset MS (POMS). Method: POMS were evaluated between 2010 and 2014; demographic and clinical characteristics and cerebro-spinal fluid (CSF) findings were assessed. Results: The data of 32 patients with POMS was evaluated. The disease course was progressive without any relapse (PPMS) in 24 patients, whereas 8 patients experienced relapses (PRMS). The female/male ratio was 1 in total POMS population. The median age of onset was 40 (23–55) years in the whole group. There was no significant difference in median onset age between two subgroups (p=0.053). The most common presentation symptom was motor disturbances. Relapses occurred in the first 10 years of the disease in all patients. No difference was detected between groups according to oligoclonal band (OCB) positivity and increased IgG index (p=0.938, p=0.058) in the CSF analysis. Although the duration of disease was similar for two groups, the median EDSS score was higher in PPMS patients at the time of evaluation (p=0.020). Conclusion: This is the first study focusing on clinical course and laboratory findings of Turkish POMS patients. The comparison of clinical and laboratory findings of two groups mainly showed similar results. Future studies with larger sample size are needed to clarify if any difference exists between groups for the onset age and frequency of raised IgG index.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247–269. [CrossRef]
  • 2. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology 2009;73:1996–2002. [CrossRef]
  • 3. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, Ebers GC. The natural history of multiple sclerosis: a geographically based study 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999;122 (Pt 10):1941–1950.
  • 4. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC; Canadian Collaborative Study Group. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci USA 2003;100:12877–12882. [CrossRef]
  • 5. Kurtzke JF. Geographic distribution of multiple sclerosis: an update with special reference to Europe and the Mediterranean region. Acta Neurol Scand 1980;62:65–80.
  • 6. Hammond SR, McLeod JG, Millingen KS, Stewart-Wynne EG, English D, Holland JT, McCall MG. The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 1988;111( Pt 1):1–25.
  • 7. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302. [CrossRef]
  • 8. Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122( Pt 4):625–39.
  • 9. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005;65:1919–1923. [CrossRef]
  • 10. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129(Pt 3):606–616. [CrossRef]
  • 11. Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 2003;126(Pt 11):2528–2536. [CrossRef]
  • 12. Andersson PB, Waubant E, Gee L, Goodkin DE. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol 1999;56:1138–1142.
  • 13. Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1075–1084. [CrossRef]
  • 14. Thompson A. Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other fo rms of MS, diagnostic criteria, pros and cons of progressive diagnosis. Multiple Sclerosis 2004;10 Suppl 1:S2–S7.
  • 15. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007;6:903–912. [CrossRef]
  • 16. McDonnell GV, Hawkins SA. Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J Neurol Neurosurg Psychiatry 1998;64:451–454.
  • 17. Lau KK, Wong WW, Sheng B, Yu IT, Fung BH, Li HL, Ma KF, Wong LK, Li PC. The clinical course of multiple sclerosis patients in Hong Kong. J Neurol Sci 2008:15;268:78–82. [CrossRef]
  • 18. Harding KE, Wardle M, Moore P, Tomassini V, Pickersgill T, Ben-Shlomo Y, Robertson NP. Modelling the natural history of primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2015;86:13–19. [CrossRef]
  • 19. Wolinsky JS; PROMiSe Study Group. The diagnosis of primary progressive multiple sclerosis. J Neurol Sci 2003;206:145–152.
  • 20. Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D; PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14– 24. [CrossRef]
  • 21. Khan O, Caon C, Ching W, Sonenvirth E, Tselis A, Zvartau-Hind M. Clinical profile and application of diagnostic criteria in primary progressive multiple sclerosis. Mult Scler 2002;8:S33.
  • 22. Oberwahrenbrock T, Schippling S, Ringelstein M, Kaufhold F, Zimmermann H, Keser N, Young KL, Harmel J, Hartung HP, Martin R, Paul F, Aktas O, Brandt AU. Retinal damage in multiple sclerosis disease subtypes measured by highresolution optical coherence tomography. Mult Scler Int 2012;2012:530305. [CrossRef]
  • 23. Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol 2014;27:271–278. [CrossRef]
  • 24. Schlaeger R, D’Souza M, Schindler C, Grize L, Kappos L, Fuhr P. Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis. Mult Scler 2014;20:51–56. [CrossRef]
  • 25. Bieniek M, Altmann DR, Davies GR, Ingle GT, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2006;77:1036–1039. [CrossRef]
  • 26. Gass A, Rocca MA, Agosta F, Ciccarelli O, Chard D, Valsasina P, Brooks JC, Bischof A, Eisele P, Kappos L, Barkhof F, Filippi M; MAGNIMS Study Group. MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurol 2015;14:443–454. [CrossRef]
  • 27. Zephir H, de Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, Malikova I, Pelletier J, Sénéchal O, Vermersch P. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004;218:73–77. [CrossRef]
  • 28. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose metylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511–516.
  • 29. Bergamaschi R, Versino M, Raiola E, Citterio A, Cosi V. High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients: one year follow-up. Acta Neurol (Napoli) 1993;15:33–43.
  • 30. Araújo EA, Freitas MR. Benefit with methylprednisolone in continuous pulsetherapy in progressive primary form of multiple sclerosis: study of 11 cases in 11 years. Arq Neuropsiquiatr 2008;66:350–353.
APA KAYMAKAMZADE B, Kılıç a, KURNE A, KARABUDAK R (2019). Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course. , 23 - 26. 10.5152/npa.2017.19269
Chicago KAYMAKAMZADE Bahar,Kılıç ahmet kasım,KURNE Aslı TUNCER,KARABUDAK Rana Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course. (2019): 23 - 26. 10.5152/npa.2017.19269
MLA KAYMAKAMZADE Bahar,Kılıç ahmet kasım,KURNE Aslı TUNCER,KARABUDAK Rana Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course. , 2019, ss.23 - 26. 10.5152/npa.2017.19269
AMA KAYMAKAMZADE B,Kılıç a,KURNE A,KARABUDAK R Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course. . 2019; 23 - 26. 10.5152/npa.2017.19269
Vancouver KAYMAKAMZADE B,Kılıç a,KURNE A,KARABUDAK R Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course. . 2019; 23 - 26. 10.5152/npa.2017.19269
IEEE KAYMAKAMZADE B,Kılıç a,KURNE A,KARABUDAK R "Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course." , ss.23 - 26, 2019. 10.5152/npa.2017.19269
ISNAD KAYMAKAMZADE, Bahar vd. "Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course". (2019), 23-26. https://doi.org/10.5152/npa.2017.19269
APA KAYMAKAMZADE B, Kılıç a, KURNE A, KARABUDAK R (2019). Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course. Nöropsikiyatri Arşivi, 56(1), 23 - 26. 10.5152/npa.2017.19269
Chicago KAYMAKAMZADE Bahar,Kılıç ahmet kasım,KURNE Aslı TUNCER,KARABUDAK Rana Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course. Nöropsikiyatri Arşivi 56, no.1 (2019): 23 - 26. 10.5152/npa.2017.19269
MLA KAYMAKAMZADE Bahar,Kılıç ahmet kasım,KURNE Aslı TUNCER,KARABUDAK Rana Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course. Nöropsikiyatri Arşivi, vol.56, no.1, 2019, ss.23 - 26. 10.5152/npa.2017.19269
AMA KAYMAKAMZADE B,Kılıç a,KURNE A,KARABUDAK R Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course. Nöropsikiyatri Arşivi. 2019; 56(1): 23 - 26. 10.5152/npa.2017.19269
Vancouver KAYMAKAMZADE B,Kılıç a,KURNE A,KARABUDAK R Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course. Nöropsikiyatri Arşivi. 2019; 56(1): 23 - 26. 10.5152/npa.2017.19269
IEEE KAYMAKAMZADE B,Kılıç a,KURNE A,KARABUDAK R "Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course." Nöropsikiyatri Arşivi, 56, ss.23 - 26, 2019. 10.5152/npa.2017.19269
ISNAD KAYMAKAMZADE, Bahar vd. "Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course". Nöropsikiyatri Arşivi 56/1 (2019), 23-26. https://doi.org/10.5152/npa.2017.19269